T1	Participants 72 95	advanced gastric cancer
T2	Participants 258 281	gastric cancer patients
T3	Participants 349 376	63 gastric cancer patients.
T4	Participants 417 651	Group F, 16 cases who received a single administration of 5-fluorouracil (5-FU); Group C, 15 cases who received a single administration of cis-diamminedichloroplatinum (CDDP; cisplatin); Group FC, 16 cases who received both 5-FU+CDDP;
T5	Participants 656 715	a Control group, 16 cases who did not receive chemotherapy.